EGFR and central nervous system cancer: In the EGFR-low glioma subset (N = 115), EFEMP1 data analysis showed a significant, unfavorable, patient prognosis, with HR = 1.7 and a 95% confidence interval = (1.1 – 2.7), while in the EGFR-high glioma subset (N = 51), the EFEMP1 data lacked any significant prognostic value (Figure 6C-D).